Oura Inc. S-1IPO prospectus

Executive Summary

Oura sells smart rings and recurring health-insight memberships to consumers, with retail, employer and healthcare partners extending its reach. It is expanding beyond sleep tracking into personalized health guidance, using continuous biometric data, artificial intelligence and integrations with other health services. Revenue is growing rapidly but more slowly than in FY2025; higher subscription margins are helping, while spending on product development and customer acquisition limits profitability. The IPO remains unpriced, so buyers cannot yet assess valuation or ownership offered; the investment case requires durable membership retention, successful hardware launches and disciplined capital allocation after substantial shareholder buybacks.

Business Model and Growth Drivers

Hardware brings customers into Oura’s ecosystem; Membership monetizes their continuing engagement. Management intends hardware sales to recover customer-acquisition costs upfront. In 9M FY2026, hardware contributed 80% of revenue, while higher-margin Membership generated $241M, up 121%, and an 89% gross margin. Hardware revenue increased $385M to $974M, accounting for most incremental sales.

The ring and app cover sleep, recovery, activity, stress, cardiovascular health, metabolic health and women’s health. Oura Advisor provides conversational health guidance; integrations include Natural Cycles and Dexcom’s Stelo glucose biosensor. Ring 5 launched on 6/4/2026 and is described as ≈40% smaller than its predecessor. Oura reports ≈99% heart-rate accuracy and ≈96% sleep accuracy, but most offerings provide wellness insights rather than authorized medical-device functionality. Its blood-pressure algorithm remains investigational. Nearly 42 billion hours of biometric data support personalized baselines and product development.

Paid Members doubled to ≈5.0M by 6/30/2026, while ring sales increased to 3.1M from 1.8M in the comparable nine months. ≈94% of activations convert to paid membership. Weighted-average retention after 12 months was ≈85%, including reactivated members; Paid Members exclude trials but include limited concessions and payment-grace periods.

Women represent ≈72% of members. Retail supplied ≈49% of interim hardware revenue, while international markets contributed less than 20%, supporting management’s distribution-expansion strategy. Two customers accounted for 12% and 10% of total revenue, making channel relationships consequential.

The Offering

• This preliminary IPO has no price range, offering share count or post-offering share count. Gross proceeds, implied market capitalization, revenue multiple, buyer ownership and fully diluted valuation therefore cannot yet be calculated.
• Both company and existing-holder shares are contemplated; only primary sales fund Oura. Goldman Sachs leads the underwriting syndicate. Oura has applied for Nasdaq listing as OURA; the additional-share option covers selling-stockholder shares for 30 days.
• Proceeds are intended for technology, working capital, operating expenses, capital expenditures and employee share-award tax withholding. Management has broad discretion, including possible acquisitions; secondary proceeds go to selling holders.
• Before the IPO, preferred shares and Eli Lilly’s $50.0M investment convertible into shares will convert, and eligible restricted stock units will settle after withholding shares for taxes. These events change capitalization before offering proceeds are added. Outstanding options cover 10.9M shares and restricted stock units cover 18.8M, some subject to IPO settlement.
• Per-share tangible-asset backing and dilution remain unquantified. Lock-ups are expected for officers, directors and substantially all holders, but their duration is unspecified. A directed program for employees and management-designated participants is contemplated; those purchases are exempt from lock-up.

Key Financial Highlights

Fiscal years end September 30; interim periods end June 30. Dollar amounts are historical, in $M. After-IPO balances remain unspecified.

¹ Operating cash flow less property, equipment and intangible-asset purchases.

• Spending: Interim marketing reached $258M and R&D $207M, up 84% and 105%. Q3 FY2026 nevertheless produced a $9.97M net loss, showing that year-to-date profitability is not assured.
• Taxes and warranties: FY2025’s $25.4M deferred-tax valuation adjustment largely erased operating profit; the interim effective tax rate subsequently fell to 13.3%. FY2025 warranty provisions reached $103M vs $12.6M, helping explain the annual margin deterioration.
• Cash quality: Interim operating cash flow included $177M from accrued liabilities and $52.4M from deferred revenue—cash collected before services are delivered.
• Capital bridge: Interim buybacks consumed $1.17B. Preferred repurchases created a $985M accounting dividend, not an operating expense, within the $1.63B accumulated deficit. Preferred stock of $1.50B sits outside stockholders’ equity before conversion; conversion moves it into equity without adding cash. Offering proceeds then add cash, partly offset by tax withholding.

Governance and Control

• Common shares carry one vote each. Eight of ten planned directors are independent, but staggered terms and supermajority requirements impede shareholder-led changes.
• Annual reserve increases may add up to 5% for incentive awards and 1% for employee share purchases, creating continuing dilution beyond outstanding awards.
• Related-party dealings include a $65.0M preferred repurchase from Forerunner-affiliated funds and $3.5M of CFO loans, repaid in 7/2026. These warrant scrutiny of capital-allocation oversight.

Risk Assessment

• Product reliability: Ring 4 battery problems required replacements; the latest warranty reserve of $132M shows the continuing cost exposure.
• Patent litigation: Samsung seeks restrictions on ring imports, while Omni MedSci seeks ≈$120M in damages; either dispute could disrupt economics or availability.
• Retention and competition: Hardware demand feeds subscriptions, so weaker launches or cheaper subscription-free alternatives could impair both revenue streams.
• Health-data trust and regulation: Sensitive reproductive and biometric data, artificial-intelligence guidance and investigational features expose Oura to privacy failures and commercialization restrictions.
• Supply and distribution: Limited-source manufacturing and retailers without meaningful minimum purchases increase shortage, inventory and channel-concentration exposure.
• Capital allocation: Buybacks have depleted liquidity despite strong operating cash generation, while secured borrowing places intellectual property among lenders’ collateral.

What to Watch

• Membership durability: Retention is ≈85%; sustained retention and activation conversion would validate recurring revenue, while deterioration would weaken it.
• Ring 5 quality: Later warranty claims and reserves should show whether newer cohorts genuinely reduce replacement costs.
• Distribution expansion: International hardware remains below 20%; broader geographic sales would validate localization, while continued concentration would limit the expansion thesis.
• Cash deployment: Operating cash generation should fund investment without renewed debt-financed payouts; further large repurchases would weaken that discipline.